Boca Raton Clinical Trials
First Choice Neurology Research Center 32
First Choice Neurology Research Center 32 offers clinical trials for Migraines, Dementia, Myasthenia Gravis, and other neurological disorders.
Migraine Clinical Studies
AbbVie
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of Ubrogepant for the preventive treatment of menstrual migraine with an open-label extension.
Ipsen CLIN-10200-454
A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults.
Myasthenia Gravis Clinical Study
Argenx BV-ARGX
A randomized, double-blinded, placebo-controlled, Phase 3, parallel-group design study evaluating the efficacy and safety of Efgartigimod PH20 SC administered by prefilled syringe in adult participants with Ocular Myasthenia Gravis.
Multiple Sclerosis Clinical Study
Sanofi FREXALT
Master protocol of two independent, randomized, double-blind, Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of Multiple Sclerosis.
Sanofi FREVIVA
A randomized, double-blind, Phase 3 study comparing the efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive Multiple Sclerosis.
Amgen ABP-692
A randomized, double-blind, parallel-group study to compare Pharmacokinetics, Pharmacodynamics, clinical effects, and safety between ABP 692 and Ocrevus (Ocrelizumab) in subjects with relapsing-remitting Multiple Sclerosis.
Novartis COMB157Q12301
An open-label, randomized, parallel group, non-inferiority study to investigate the pharmacokinetics, pharmacodynamics, safety, and tolerability of a new maintenance dosing regimen of ofatumumab, followed by extended treatment in participants with relapsing multiple sclerosis.
Dementia Clinical Studies
American College of Radiology
Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET).
MapLight ML-007C-MA-221
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis.
Contact First Choice Neurology Research Center 32
Neurology Office of South Florida, LLC
9970 Central Park Blvd., Suite 207
Boca Raton, FL 33428
Phone: (561) 482-1027 Ext. 9
Fax: (561) 613-6476
Providers:
Brian Costell, MD
Yefim Cavalier, DO
Brian Steingo, MD
Renata Chalfin, MD
Yael Subar-Hack, MD
Meghan Jacobs, PsyD
Contact:
Melinda Campos, CRC Research Dept.
(561) 482-1027 Ext. 9
mcampos@fcneurology.net